The Botulinum neurotoxin Type A has already been approved in Germany since May 2005 for the indications blepharospasm (dystonia of the eyelid) and cervical dystonia of a predominantly rotational form (spasmodic torticollis, wryneck).
Outside of Europe, approval for these indications exists for Argentina and Mexico. In Argentina, the product is also approved for the temporary improvement of the glabellar frown lines in aesthetic dermatology.
"Botulinum neurotoxin Type A is a strategically important active ingredient for us," says Dr. Martin ZÃ¼gel, CEO of Merz Pharmaceuticals. "We are pleased with the Committee's recommendation and will be intensifying our market launch activities and targeted promotions for success in these countries."
Merz specializes in drugs for the treatment of neurological and psychiatric illnesses and is a leader in the field of Alzheimer's research. Merz developed Memantine, the world's first drug for the treatment of moderate to severe stages of Alzheimer's disease. Among drugs to combat Alzheimer's, Memantine is the second-largest in the world. Another area of competence at Merz is clinical and cosmetic dermatology.
Along with the pharmaceuticals market, Merz is active in the healthcare sector outside of pharmacies as well. With its tetesept® and Merz Spezial® brands, in German-speaking countries Merz is a leading provider of products for self-medication, dietary supplements, beauty and wellness. A Merz subsidiary, Senator GmbH & Co. KGaA, is one of the leading manufacturers of high-quality promotional writing instruments worldwide.
The Merz Group employs 1,900 employees worldwide. The company achieved revenues of € 475 million in the 2005/06 fiscal year. For more information, visit www.merz.com.